WebJul 18, 2024 · 1.7.3 Offer an aromatase inhibitor as the initial adjuvant endocrine therapy for postmenopausal women with ER‑positive invasive breast cancer who are at medium or high risk of disease recurrence. Offer tamoxifen to women who are at low risk of disease recurrence, or if aromatase inhibitors are not tolerated or are contraindicated. WebPurpose: BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is associated with a decrease in risk for tubal and ovarian cancer. Hormone replacement therapy (HRT) may increase breast, ovarian, and endometrial cancer risk in the general population.
Breast screening: clinical guidelines for screening assessment
WebConsider annual mammography starting at age 40 years if relative with breast cancer aged <50 years. Consider referral to family cancer clinic or specialist cancer clinic, where … WebPurpose. With an estimated 3.8 million breast cancer survivors in the United States, obstetrician–gynecologists often are on the front lines of addressing survivorship issues, … foam couch cushion replacement
Zahid Khan - Consultant Gynaecologist and Obstetrician - LinkedIn
WebRCOG World Congress 2024. Utilise our exclusive early bird discount and secure 60+ hours of RCOG World Congress learning covering 25+ specialist areas, which you can watch live … WebMar 17, 2024 · For healthcare professionals. The British Menopause Society (BMS) is the specialist authority for menopause and post reproductive health in the UK. Established in 1989, the BMS educates, informs and guides healthcare professionals, working in both primary and secondary care, on menopause and all aspects of post reproductive health. Webthe risk of breast cancer remains elevated more than 10 years after discontinuing MHT. A modifying effect was noted for obesity. The meta-analysis showed no estrogen dosage … foam counter protector mat